BHEL Q4 results 2026: Profit jumps nearly threefold to ₹1,290 crore; declares a final dividend of ₹1.40 for FY26 LiveMint · Markets 29m ago
UCB To Acquire Candid Therapeutics For Up To $2.2 Bln To Boost Immunology Pipeline NASDAQ · Markets 1h ago